# Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

> **NCT05961644** · PHASE2,PHASE3 · RECRUITING · sponsor: **Institute of Psychiatry and Neurology, Warsaw** · enrollment: 188 (estimated)

## Conditions studied

- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis

## Interventions

- **DRUG:** Cladribine Subcutaneous Injection
- **DRUG:** 0.9% Chloride Injection Sodium

## Key facts

- **NCT ID:** NCT05961644
- **Lead sponsor:** Institute of Psychiatry and Neurology, Warsaw
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-03
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2023-07-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05961644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05961644, "Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05961644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*